Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of six-drug intensive chemotherapy for newly diagnosed pediatric parameningeal rhabdomyosarcoma with meningeal invasion
ChiCTR1800018595Phase 2Recruiting
- Sponsor
- Capital Medical University, Beijing Children's Hospital
- Start
- Oct 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, carboplatin, ifosfamide, actinomycin D, vincristine and 1 more in Parameningeal rhabdomyosarcoma (PM-RMS), sponsored by Capital Medical University, Beijing Children's Hospital. Primary endpoint: Response rate. Started Oct 2018; status: recruiting.
02
Drugs
doxorubicincarboplatinifosfamideactinomycin Dvincristine
03
Conditions
Parameningeal rhabdomyosarcoma (PM-RMS)
Beyond the preview
Go deeper on ChiCTR1800018595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018595.